SAB Biotherapeutics, Inc. (SABS) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$0

Net Income/Loss (FY2025)

$13.3M

Total Assets (FY2025)

$172.8M

Total Equity (FY2025)

$151.5M

Cash Flows from Operating Activities (FY2025)

-$44.8M

Source: SAB Biotherapeutics, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.